NasdaqCM - Nasdaq Real Time Price USD

Accelerate Diagnostics, Inc. (AXDX)

Compare
1.1200
+0.0100
+(0.90%)
At close: January 16 at 4:00:00 PM EST
Loading Chart for AXDX
DELL
  • Previous Close 1.1100
  • Open 1.1300
  • Bid 1.0700 x 100
  • Ask 1.1600 x 100
  • Day's Range 1.0469 - 1.1700
  • 52 Week Range 0.7300 - 2.0900
  • Volume 52,908
  • Avg. Volume 66,221
  • Market Cap (intraday) 28.049M
  • Beta (5Y Monthly) 0.60
  • PE Ratio (TTM) --
  • EPS (TTM) -2.5900
  • Earnings Date Mar 26, 2025 - Mar 31, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

acceleratediagnostics.com

134

Full Time Employees

December 31

Fiscal Year Ends

Recent News: AXDX

View More

Performance Overview: AXDX

Trailing total returns as of 1/16/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

AXDX
2.61%
S&P 500
0.51%

1-Year Return

AXDX
69.73%
S&P 500
24.11%

3-Year Return

AXDX
97.27%
S&P 500
27.33%

5-Year Return

AXDX
99.40%
S&P 500
80.51%

Compare To: AXDX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AXDX

View More

Valuation Measures

Annual
As of 1/16/2025
  • Market Cap

    28.05M

  • Enterprise Value

    66.11M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.94

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    5.55

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -75.85%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    12.23M

  • Net Income Avi to Common (ttm)

    -37.91M

  • Diluted EPS (ttm)

    -2.5900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    9.75M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -54.67M

Research Analysis: AXDX

View More

Company Insights: AXDX

Research Reports: AXDX

View More

People Also Watch